arrow
A

Anchalee Avihingsanon

hiv-nat thai red cross aids and infectious diseases research centre
H指数:40
被引数:6,507

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Elevated lipoprotein(a), trimethylamine n-oxide, and gut dysbiosis are associated with subclinical coronary atherosclerosis independent of metabolic dysfunction-associated steatotic liver disease

高脂蛋白(a)、三甲胺N-氧化物和肠道菌群失调与代谢功能障碍相关脂肪性肝病无关的亚临床冠状动脉粥样硬化相关

2026-08-030
OAAI
Real-World Estimates of HIV Incidence From Sexual Health Clinic EMRs: Feasibility, Limitations, and Implications for Surveillance

来自性健康诊所电子病历的艾滋病病毒发病率现实世界估计:可行性、局限性及对监测的影响

2026-05-010
PRE
Prognostic value of ankle-brachial index and cardio-ankle vascular index for mortality and cardiovascular events in older people with HIV on long-term ART

踝臂指数和 cardio-ankle vascular index 对长期接受抗逆转录病毒治疗的人的死亡率和心血管事件的预后价值

2026-04-010
PRE
Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials

美国启动现代抗逆转录病毒疗法的人免疫缺陷病毒感染者的高血压风险:五项临床试验血压数据的合并分析

2026-03-010
OA
Low Cholesterol Associated With TB in People Living With HIV in an Asia-Pacific Cohort
2026-01-010
PRE
Kidney dysfunction in adults living with HIV and HBV: a 10-year retrospective cohort study across seven Asia-Pacific countries

人类免疫缺陷病毒和乙型肝炎病毒感染者肾功能障碍:一项跨越亚太地区七个国家的十年回顾性队列研究

2025-12-120
PRE
Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients

利福喷丁每月一次用于潜伏性结核病治疗的药代动力学和耐受性研究:在血液透析患者中的研究

2025-12-010
PRE
The Association Between Genetic Polymorphisms of UGT1A1, ABCG2, and NR1I2 and Dolutegravir Pharmacokinetic Parameters in Thai People Living with HIV

UGT1A1、ABCG2和NR1I2基因多态性与泰国人类免疫缺陷病毒感染者达芦那韦药代动力学参数之间的关联

2025-11-200
OAAI
NAT2 Polymorphisms and Antituberculosis-Induced Hepatotoxicity in Thai People Living With HIV: Insights From a Pharmacogenetic-Pharmacokinetic Cohort Study

NAT2多态性与抗结核药物诱导的肝毒性:基于泰国人类免疫缺陷病毒感染者药效遗传-药代动力学队列研究的见解

2025-10-010
PRE
Immunogenicity and safety of ‘Comvigen’, a bivalent SARS-CoV-2 vaccine, in comparison to Comirnaty bivalent vaccine in Thailand: a phase 2, non-inferiority randomised trial

‘Comvigen’二价SARS-CoV-2疫苗的免疫原性和安全性,与Comirnaty二价疫苗在泰国的比较:一项2期非劣效性随机试验

2025-08-150
PREAI
A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study

一项随机试验,旨在比较多替拉韦联合增强型达鲁那韦与推荐的标准抗逆转录病毒方案在HIV-1感染者中的疗效,这些患者的一线非核苷类逆转录酶抑制剂疗法已失败:D2EFT研究的最终96周结果

2025-08-010
OAAI
Kinetics and Predictors of Hepatitis B Surface Antigen (HBsAg) Loss After Commencing Hepatitis B Virus (HBV)-Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection

乙型肝炎表面抗原(HBsAg)清除的动力学及预测因素:在HIV和慢性乙型肝炎病毒共感染背景下启动抗乙型肝炎病毒活性的抗逆转录病毒疗法(ART)后的情况

2025-06-016
OA